Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab with concurrent PD-1 blockade in metastatic melanoma with bone involvement
2016-001925-15Phase 4Completed
- Sponsor
- Alcedis
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of denosumab, nivolumab, pembrolizumab in melanoma, sponsored by Alcedis. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2016-001925-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001925-15.